An Open label, International, Multicenter, Dose Escalating Phase 1/2 Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genmab; Janssen Research & Development; Janssen-Cilag
- 26 Mar 2024 Planned End Date changed from 1 Mar 2024 to 31 Aug 2024.
- 30 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.
- 10 Oct 2023 Planned End Date changed from 31 Dec 2025 to 1 Jan 2024.